MetaCure
 |
|
| Private | |
| Industry | Medical Devices and Medical Technology |
| Founded | 2003 |
| Founder | Dr. Shlomo Ben-Haim |
|
Key people
|
Dr. Mateusz Zelewski (General Manager) |
| Products | DIAMOND System (formerly the Tantalus System) |
| Website | Metacure Ltd. Website |
MetaCure is a privately held global medical device company that develops and markets minimally invasive treatments for type 2 Diabetes and obesity by regulating postprandial sugar metabolism and satiety through the use of gastric electrical stimulation.
Founded in 2003 by Dr. Shlomo Ben-Haim, MetaCure has developed an implantable medical device system for the treatment of type 2 diabetes and obesity. The company’s DIAMOND System (formerly called Tantalus) uses a platform technology that provides non-excitatory (non-pacing) stimulation to tissue that produces a physiological response. The electrical stimulation, which is applied to the stomach muscles, is called gastric contractility modulation (GCM). Through GCM, DIAMOND improves how glucose is metabolized in the body. This platform technology was first applied to the treatment of heart failure. When applied to heart tissue, the electrical stimulation is known as cardiac contractility modulation.
MetaCure is one of the portfolio companies of the Hobart Group, which invests in medical device companies.
The International Diabetes Federation estimates that diabetes affects 566 million people worldwide, with 90%-95% of people having type 2 Diabetes. The prevalence of diabetes is expected to increase to over 770 million in 2035. This rise in prevalence is expected to occur because of the global obesity epidemic. Obesity is a major risk factor for the onset of diabetes. In fact, obesity and abdominal fat is thought to account for 80%-90% of type 2 diabetes cases, which has led to the creation of the term “diabesity”. The World Health Organization (WHO) estimates that more than 60% of adult Americans and approximately half of female Europeans are overweight and obese.
Controlling post-prandial blood glucose concentration is a primary treatment goal for type 2 diabetes. Blood glucose concentration is assessed by measuring the amount of glycated hemoglobin (HbA1c) in the blood. The UK Prospective Diabetes Study (UKPDS) found that a 1% reduction in HbA1c lowers the risk for diabetes-related mortality by 21% and myocardial infarction (MI) by 14%. Reducing HbA1c by 1% also lowers the risk of microvascular complications, such as amputation of a limb, which is a common complication of diabetes.
...
Wikipedia